79,075 Eli Lilly and Company $LLY Shares Purchased by Pictet Asset Management Holding SA

Posted by Geri Gentry on Nov 8th, 2026

Eli Lilly and Company logo Pictet Asset Management Holding SA grew its position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 10.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 834,060 shares of the company’s stock after acquiring an additional 79,075 shares during the quarter. Eli Lilly and Company accounts for approximately 0.9% of Pictet Asset Management Holding SA’s portfolio, making the stock its 16th largest holding. Pictet Asset Management Holding SA’s holdings in Eli Lilly and Company were worth $965,373,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Bank of America Corp DE bought a new position in shares of Eli Lilly and Company during the second quarter valued at about $13,522,666,000. Jupiter Topco LLC bought a new stake in Eli Lilly and Company in the 2nd quarter worth about $4,667,180,000. Fifth Third Bancorp grew its position in Eli Lilly and Company by 321.3% in the 1st quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company’s stock worth $1,805,959,000 after purchasing an additional 1,497,423 shares in the last quarter. Corient Private Wealth LP bought a new stake in Eli Lilly and Company in the 2nd quarter worth about $764,116,000. Finally, BlackRock Inc. increased its stake in Eli Lilly and Company by 1.6% in the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock valued at $81,009,981,000 after buying an additional 1,046,558 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: Lilly and Hims & Hers agreed to offer FDA-approved Zepbound and Foundayo through Hims & Hers’ telehealth platform. Eligible patients with a prescription can access Lilly’s self-pay prices—reportedly starting at $149—without leaving the platform. The deal could widen patient access and Lilly’s reach in the competitive obesity-treatment market. Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
Positive Sentiment: New Phase 3 results for investigational retatrutide showed substantial reductions in weight and knee pain among adults with obesity and knee osteoarthritis. Lilly also reported positive Phase 3b results for combining Taltz and Zepbound in people with psoriatic arthritis and obesity, supporting the potential of its medicines in additional patient groups. Lilly to showcase new retatrutide, Taltz and Zepbound data
Negative Sentiment: Price competition across the GLP-1 market remains a risk to Lilly’s growth and drug margins, as branded treatments compete with lower-priced options and providers seek self-pay patients. Eli Lilly’s GLP-1 franchise faces growing price competition

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 2,000 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the transaction, the chief accounting officer directly owned 1,526 shares of the company’s stock, valued at approximately $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the firm’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the sale, the executive vice president directly owned 54,147 shares of the company’s stock, valued at $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 13,500 shares of company stock valued at $17,020,770. 0.14% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Leerink Partners lifted their target price on shares of Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 21st. Cantor Fitzgerald upped their target price on Eli Lilly and Company from $1,440.00 to $1,600.00 and gave the company an “overweight” rating in a report on Monday, November 2nd. Scotiabank increased their price target on Eli Lilly and Company from $1,300.00 to $1,605.00 and gave the company a “sector outperform” rating in a research report on Friday, October 30th. Guggenheim increased their price target on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a “buy” rating in a research report on Friday, September 18th. Finally, Berenberg Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $1,400.00 price target on the stock in a report on Tuesday, September 15th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $1,404.14.

Check Out Our Latest Stock Report on Eli Lilly and Company

Eli Lilly and Company Price Performance

LLY opened at $1,372.15 on Friday. Eli Lilly and Company has a fifty-two week low of $850.51 and a fifty-two week high of $1,453.00. The firm has a 50-day moving average of $1,215.24 and a 200 day moving average of $1,101.16. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39. The firm has a market cap of $1.29 trillion, a P/E ratio of 44.54, a PEG ratio of 1.69 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The company reported $7.48 EPS for the quarter, topping the consensus estimate of $5.71 by $1.77. The business had revenue of $24.40 billion for the quarter, compared to analyst estimates of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The company’s revenue for the quarter was up 38.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $7.02 earnings per share. On average, research analysts expect that Eli Lilly and Company will post 35.70 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be paid a dividend of $1.73 per share. The ex-dividend date is Friday, November 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 22.46%.

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management.

The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Founded in Indianapolis in 1876 by Colonel Eli Lilly, the company is headquartered in the city and serves patients in markets around the world.